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hemodilutionAbstract Purpose: The purpose was to study the effect of recombinant human erythropoietin
(rHuEPO) and iron or iron alone with acute normovolemic hemodilution (ANH) on blood trans-
fusion requirements in elective myomectomy patients.
Methods: Ninety female patients scheduled for myomectomy and ANH after induction of general
anesthesia were randomly allocated into three equal groups (30 patients each); Group I (control
group): Patients scheduled for ANH alone; Group II: Patients received oral ferrous iron sulfate
320 mg tablets twice daily for 2 weeks before surgery; and Group III: Patients received oral ferrous
iron sulfate 320 mg tablets twice daily and recombinant human erythropoietin (rHuEPO) in a dose
of 100 IU/kg subcutaneously twice a week for 2 weeks before surgery.
Results: There was a significant increase in Hb (g/dL) and Hct % (p< 0.0001) in groups II and III
compared to group I, and in group III compared to group II at all the predetermined times. There
was a significant increase in blood volume that can be removed by ANH (ml) in groups II (1250
± 280) and III (1986.7 ± 292.8) compared to group I (987. 4 ± 176.6), and in group III compared
to group II (p< 0.001). The median number of blood units removed by ANH was significantly
increased in group III {3 (1–3)} compared to groups I and II {2 (1–3)} (p< 0.001). The number
of patients who received homologous blood transfusion was decreased in group III [1 (3.33%)] com-
pared to the two other groups, and in group II [5 (16.7%)] compared to group I [10 (33.3%)].
Conclusion: Preoperative iron alone or iron and erythropoietin added to acute normovolemic hemod-
ilution help to reduce the need for allogenic blood transfusion inmyomectomy patients. Further studies
are needed to evaluate their use in older patients with higher risk for thrombosis and hypertension.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists., Egypt.
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Homologous blood transfusion faces many difficulties includ-
ing the safety, high costs and limited supply. So, there is a need
to minimize transfusion of blood components [1], and a restric-
tive transfusion strategy in hemodynamically stable patients is
recommended [2].
Acute normovolemic hemodilution (ANH) has the benefit
of reducing blood loss, as whole blood is shed perioperatively
at lower hematocrit (% Hct) values. Also, platelets and coag-
ulation factors remain functional because the blood collected
by ANH is returned to the patient within 8 h of collection
and is stored at room temperature in the operating room. In
addition, testing the blood units is not essential [3].
The most important risk factor for blood transfusion is
pre-existing anemia [4] which may be present in about 75%
of patients scheduled for elective surgery [5]. The most com-
mon cause of impaired erythropoiesis is absolute deficiency
of iron stores especially in young children, pregnant and pre-
menopausal women and elderly people [6]. Their management
depends on repletion of iron stores and most patients respond
well to oral iron therapy [7]. Erythropoietin increases the
preoperative hemoglobin (Hb), hematocrit % (Hct %), and
production of red blood cells (RBCs) [8]. So, the aim of this
work was to study the effect of adding erythropoietin and iron
or iron alone to acute normovolemic hemodilution (ANH) on
blood transfusion requirements in elective myomectomy
patients.
2. Patients and methods
This study was carried out in Tanta University Hospital from
September 2012 to September 2013 on 90 female patients
scheduled for elective myomectomy at the Gynecology and
Obstetric Department after obtaining an institutional board
approval. A written informed consent was obtained from each
patient or their closest relative and all the data in the study
were confidential; every patient had a secret code and private
file and the results were used for scientific purpose only.
The trial is registered in the Australian New Zealand
Clinical Trials Registry: ACTRN12615000152527.
The primary end point of the study in each group was the
percentage of patients who received homologous blood trans-
fusion and the number of homologous blood units they
received in the first 3 postoperative days. The sample size for
each group was calculated based on the data of a previous
pilot study in our institute. Thirty patients in each group were
required for erythropoietin and iron to decrease the percentage
of homologous blood transfusion by about 30%, with 90%
power and a cutoff of 0.05% for statistical significance.
Patients aged >18 and <60 years with hemoglobin level
>11 g/dL at the time of ANH were included in this study,
while, patients who refused to participate in the study and
received blood or blood components in the preceding 4 weeks,
with severe hepatic, renal or heart disease were excluded from
the study.
Patients were randomly allocated into three equal groups
(30 patients each): Group I (control group): Patients scheduled
for ANH alone after induction of general anesthesia; Group II:
Patients received oral ferrous iron sulfate 320 mg tablets twice
daily for 2 weeks before surgery and scheduled for ANH afterinduction of general anesthesia; and Group III: Patients
received oral ferrous iron sulfate 320 mg tablets twice daily
and recombinant human erythropoietin (rHuEPO) in a dose
of 100 IU/kg subcutaneously twice a week for 2 weeks before
surgery and scheduled for ANH after induction of general
anesthesia. Randomization between groups II and III
(treatment groups) was done using closed sealed envelops
and computer generated random numbers two weeks before
surgery, while, patients of the control group were selected
randomly at the time of operation. A blinded nurse, who did
not participate in data collection read the patient’s number.
The ANH was started just after tracheal intubation, and the
volume to be withdrawn was calculated (maximum 3 units),
while maintaining the Hct level >28%. The first 1000 cc of
blood withdrawn was replaced with equal volume of
hydroxy-ethyl starch 6%, then any additional blood was
replaced with crystalloid solution in the ratio of 3:1.
Hemoglobin (Hb) and hematocrit (Hct) % were measured
preoperatively 2 weeks (baseline values) and one week before
surgery; intra-operatively just before induction of anesthesia,
immediately after ANH then at 30, 60, 90, 120 min and at
the end of surgery; and Postoperatively; after 2 h and, once
daily for the first 3 days. The number of patients in each group
who received homologous blood transfusion and, the number
of units they received was recorded.
The volume of blood that could be withdrawn during ANH
from each patient was calculated using the following formula
[9]:
V ¼ EBV Hi Hfð Þ
Hav
V=Volume of blood that could be removed. EBV = Esti-
mated blood volume. Hi = initial hematocrit level. Hf = the
target hematocrit level following ANH. Hav = the average
hematocrit level of Hi and Hf.
The number of blood units withdrawn by ANH was
recorded, and the volume of blood loss was estimated by esti-
mation of blood in the surgical sponges (5 mildly, 10? mod-
erately, and 15? severely soaked) and pads (50?mildly,
100? moderately, and 150? severely soaked) and, by
observing the volume of blood in the suction apparatus and
the surgical drains.
Blood transfusion was given if Hb level was <8 g/dL and,
if there was abnormal ECG, ischemic heart disease or obstruc-
tive lung disease and the Hb level was 8–10 g/dL. No transfu-
sion was given if Hb level was >10 g/dL [10]. If the patient was
in-need for blood transfusion, the blood removed by ANH was
given first, starting with the last unit collected then, homolo-
gous blood. At the end of surgery all autologous blood units
were returned to the patient.
All patients were pre-medicated with 0.01 mg/kg midazolam
before induction of anesthesia and monitored for ECG, oxygen
saturation, capnograph and non-invasive blood pressure. A uri-
nary catheter was inserted for collection of urine output. The
patients were pre-oxygenated with oxygen 100% for 5 min, then
anesthesia was induced with 2 mg/kg propofol and 1 lg/kg fen-
tanyl and tracheal intubation was facilitated with cisatracurium
0.3 mg/kg. Anesthesia was maintained with oxygen 100%,
isoflurane 1–1.5%, fentanyl 0.5 lg/kg every 30 min and incre-
mental doses of cisatracurium for muscle relaxation and
mechanical ventilation to maintain normocapnia. At the end
of surgery, anesthesia was discontinued and muscle relaxants
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Figure 1 A participant flow diagram.
Iron or iron and erythropoietin with ANH 23were reversed with neostigmine 0.04 mg/kg and atropine
0.01 mg/kg. The patient was extubated when she was fully
awake. The occurrence of any complication was recorded.
The data were analyzed using SPSS (version 20), quantita-
tive data were expressed as mean ± SD (for age, weight, pre-
operative platelet count, duration of anesthesia, Hb (g/dL),
Hct %, estimated blood volume, volume of blood that can
be removed by ANH, and volume of blood loss) and analyzed
using F Test for comparison within the same group and among
the three groups, and Tukey’s test is used as post hoc test and
independent-t-test for comparison between the groups III and
II for Hb (g/dL) and Hct % preoperatively. The number of
blood units removed by ANH (did not follow the normal dis-
tribution) was expressed as median (range) and Kruskal–Wal-
lis H test was used for comparison among the studied groups,
while, the ASA, the number of patients who received homolo-
gous blood transfusion, and complications were expressed as
number %. P< 0.05 was considered statistically significant.
3. Results
The studied groups were comparable for age, weight, ASA
state, preoperative platelet count and time of anesthesia
(p> 0.05) (Table 1) (Fig. 1).
Preoperatively in groups II and III there was a significant
increase in the values of Hb (g/dL) and Hct % 1 and 2 weeks
after treatment compared to their baseline values in both
groups; the values after the second week were significantly
higher than those after the first week in both groups
(p< 0.001). The two groups were comparable for the baseline
Hb (g/dL) (p= 0.572) and Hct % (p= 0.108) then, there was
a significant increase in the mean values of Hb in group III
compared to group II after 1 (p= 0.001) and 2 weeks
(p< 0.0001) and Hct % (p= 0.002 and <0.001) after 1 and
2 weeks respectively (Figs. 2 and 3). The values of Hb (g/dL)
and Hct % in groups II and III were significantly higher com-
pared to group I, and higher in group III compared to group II
(p< 0.0001) at all the predetermined times during intra-
operative and post-operative periods (Figs. 4–7).
The volume of blood that can be removed by ANH (ml)
was increased significantly in groups II and III compared to
group I, and in group III compared to group II (p< 0.001).
The median number of blood units removed by ANH was
increased significantly in group III compared to groups I and
II (p< 0.001), while, there was no significant difference
among the three studied groups as regards the estimated blood
volume (p= 0.7) and the blood loss (p= 0.5) (Table 2).Table 1 Patient characteristics and duration of anesthesia (minutes
Group I (n= 30) Group II (n
Age (years) 39.9 ± 6.5 41.1 ± 6.8
Weight (kg) 82.9 ± 9.3 83.5 ± 9
ASA: I 21 (70%) 21 (70%)
ASA: II 9 (30%) 9 (30%)
Preoperative platelet count 238,033.33 ± 18,334.97 231,433.33 ±
Duration of anesthesia (minutes) 139.3 ± 12.3 128.2 ± 12.
Data are expressed as mean ± SD except ASA which is expressed as nu
Significant P< 0.05.
X2 = Chi square test.As regards the number of patients who did not receive
homologous blood units, it was increased significantly in group
III [29 (96.66%)] compared to the two other groups, and in
group II [25 (83.33%)], compared to group I [20 (66.66%)].
Consequently the number of patients who received homolo-
gous blood transfusion was decreased in group III [1
(3.33%)], compared to the two other groups and in group II
[5 (16.7%)], compared to group I [10 (33.3%)] (Fig. 8).
There were few complications related to oral iron therapy; 8
(26.6%) patients in group II and 7 (23.3%) patients in group
III had constipation, while, 5 (16.6) patients in group II and
6 (20%) patients in group III had heartburn. There were no) in the studied groups.
= 30) Group III (n= 30) Test of significance P value
42.4 ± 7 F= 1.1 0.4
82.8 ± 8.4 F= 0.1 0.9
22 (73%) X2 = 0.1 0.9
8 (26.7%)
23,872.77 235,366.67 ± 19,770.2 F= 0.765 0.468
6 139.2 ± 13.4 F= 0.1 0.9
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Figure 2 Preoperative Hb concentration (g/dL) in groups II and
III.
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Figure 3 Preoperative hematocrit % (Hct %) in groups II and
III.
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Figure 4 Intra-operative Hb concentration (g/dL) in the studied
groups.
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Figure 5 Intra-operative hematocrit % (Hct %) in the studied
groups.
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Figure 6 Post-operative Hb (g/dL) concentrations in the studied
groups.
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Figure 7 Post-operative hematocrit % (Hct %) in the studied
groups.
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Table 2 ANH related blood volumes (ml) in the studied groups.
Group I (n= 30) Group II (n= 30) Group III (n= 30) P value
Estimated blood volume (ml) 5803 ± 648.5 5926.7 ± 667.7 5796 ± 584.6 0.7
Volume that can be removed by ANH (ml) 987.4 ± 176.6 1250 ± 280* 1986.7 ± 292.8** <0.0001
Blood units removed by ANH (n): 2 (1–3) 2 (1–3) 3** (1–3) <0.0001
Blood loss (ml) 711.7 ± 153.5 700 ± 155.4 670 ± 143.6 0.5
Data are expressed as mean ± SD except blood units removed by ANH which is expressed as median and range.
Significant difference p< 0.05.
* Significant difference between groups I and II.
** Significant difference between group III and each of I and II.
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Figure 8 Homologous blood transfusion in all the studied
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hypertension or thrombosis.
4. Discussion
As regards the Hb and Hct % in the present study, preopera-
tively, one and two weeks after treatment, there was a signifi-
cant increase in Hb and Hct % in groups II and III compared
to their baseline values which can be explained by the fact that
normal heme production and erythropoiesis depend on ade-
quate iron stores [11]. This is in agreement with the study of
Prasad et al. [12], and Yang et al. [13], while, Mundy et al.
[14] found that oral ferrous sulfate was not effective in treat-
ment of anemia associated with hip or knee surgeries. They
postulated that the inflammatory response to surgical trauma
affects iron metabolism through the release of interleukins,
tumor necrosis factor and endotoxins, and Parker [15], and
Lachance et al. [16] found similar results. This may be attrib-
uted to the different patient population in those studies, older
patients with orthopedic trauma, while the patients in the pre-
sent study were younger with chronic blood loss.
There was a significant increase in the mean values of Hb
and Hct % in group III compared to group II after 1 and
2 weeks of treatment which could be explained on the basis
of the role of erythropoietin in erythropoiesis as it affects pos-
itively the last step of erythrocyte production in mammals
through binding to its specific receptor leading to induction
of proliferation and differentiation of erythroid progenitors[17]. Similar results were obtained by Kosmadakis et al. [18],
Hudis et al. [19], Bovy et al. [20], and Silver et al. [21].
Moreover, we found a significant increase in Hb and Hct %
in groups III and II compared to group I, and in group III
compared to group II at all predetermined times in the intra-
and postoperative periods. This can be explained by the fact
that iron stores of the patients were deficient preoperatively
due to repeated blood loss so, the values of Hb and Hct %
in group II were better than those of group I. The induction
of erythropoiesis after erythropoietin therapy may exacerbate
borderline iron deficiency and oral iron supplementation is
very important to obtain the best results [22] so, the best results
were obtained with group III. The results obtained by Corwin
et al. [23], Karkouti et al. [24], Kateros et al. [25], Laffosse
et al. [26], Lepor et al. [27] and Delasotta et al. [28] are in
agreement with our results. Contrary to our results, Madi-
Jebara et al. [29] and Karkouti et al. [30] reported weak
response of erythropoietin and iron for correction of severe
postoperative anemia (despite accelerated erythropoiesis as
indicated by increased reticulocytic count). This may be caused
by the negative effect of inflammation on erythropoietin recep-
tor and the pro-inflammatory cytokines may have an inhibi-
tory effect on erythroid progenitor cells and disturb iron
metabolism in the postoperative period [31] while, we used ery-
thropoietin and iron 1 and 2 weeks preoperatively; moreover,
Madi-Jebara et al. [29] used a single low dose of erythropoietin
(300 IU) which is less than the dose used in the present study.
A significant increase in the volume of blood that could be
removed by ANH was observed in groups III and II compared
to group I, and in group III compared to group II. Also, the
median number of blood units removed by ANH was signifi-
cantly increased in group III compared to the other two
groups. Similar results were obtained by Sonzogni et al. [32]
and Bovy et al. [20].
Concerning the number of patients who received
homologous units, comparison among the studied
groups revealed that it decreased significantly in group III
compared to the other two groups. The results reported by
Corwin et al. [23], Karkouti et al. [24], Silver et al. [21],
Kateros et al. [25], Laffosse et al. [26], Yoo et al.
[33], Cladellas et al. [34] and Delasotta et al. [28] are in
agreement with our results, while, Grobmyer et al. [35] dis-
agreed with our results, as they found no significant differ-
ence in the transfusion rate between groups and this may
be due to inhibition of erythropoiesis in their patients
(abdominal and pelvic malignancies) by several mediators
including tumor necrosis factor alpha, interleukin-1 and 6
and transforming growth factor-beta [36].
26 Abd El Raheem Mostafa Dowidar et al.As regards the complications, there were few minor
complications related to oral iron therapy and could be
tolerated (did not need any treatment); 8 (26.6%) patients in
group II and 7 (23.3%) patients in group III had constipation,
while, 5 (16.6) patients in group II and 6 (20%) patients in
group III had heartburn. There were no serious complications
related to erythropoietin therapy e.g. hypertension or
thrombosis.
We conclude that, preoperative iron alone or iron and ery-
thropoietin added to acute normovolemic hemodilution help
to reduce the need for allogenic blood transfusion in myomec-
tomy patients. The study has some limitations as, the partici-
pants were middle aged females, so the safety of
erythropoietin in older, hypertensive or cardiac male patients
must be studied. Also, it is better to be repeated on a larger
sample size.
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